A Lipid-Lowering Diet Combined with Exercise is Effective for Achieving Healthy Serum Cholesterol in a Male with a Predisposition for Developing Hyperlipidemia (Dyslipidemia): A 20-Year Case Study

A Lipid-Lowering Diet Combined with Exercise is Effective for Achieving Healthy Serum Cholesterol in a Male with a Predisposition for Developing Hyperlipidemia (Dyslipidemia): A 20-Year Case Study

Loading document ...
Page
of
Loading page ...

Author(s)

Author(s): Yoshiaki Sugawara, Naomi Sano, Yuka Nishida

Download Full PDF Read Complete Article

539 1135 1-11 Volume 2 - Nov 2013

Abstract

This case-study presents data supporting the use of a combination of a lipid-lowering diet and physical aerobic exercise for achieving healthy levels of plasma triglycerides, serum total cholesterol as well as low-density and high-density lipoproteins. The blood lipid data were those of one of the authors (Y.S.) obtained from annual health testing results from 1988 to 2011. Y.S. was diagnosed with hyperlipidemia (dyslipidemia) in 1989 and decided to not take lipid-lowering drugs but rather follow a lipid-lowering diet developed by a clinical registered dietician. The test results showed that initially, the lipid-lowering diet assisted in the achievement of healthy plasma triglyceride and total cholesterol levels. However, eight years after commencement of the lipid-lowering diet (in 1997) Y.S. had his second diagnosis of hyperlipidemia. He then included a daily walking program (no less than 10,000 steps per day, 5 to 6 days/week) and later indoor bike-peddling exercise (minimum of 30 min/day, 5 days/week) as part of his treatment plan and continued with his lipid-lowering diet. This new regimen was highly effective with Y.S. achieving and maintaining a healthy level of plasma triglyceride, serum total cholesterol as well as low-density lipoprotein cholesterol.

Keywords

hyperlipidemia, dyslipidemia, lipid-lowering diet, physical aerobic exercise, lifestyle modifications, a long case study

References

  1. Endo, A. The origin of the statins. Int. Con. Series 2004, 1262, 3-8
  2. The American Heart Association. The cholesterol facts- A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990, 81, 1721-1732
  3. Scott, M.; Grundy, M.D. Cholesterol and coronary heart disease. JAMA. 1986, 256, 2849-2858
  4. The Helsinki Heart Study. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988, 260, 641-651
  5. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am. J. Cardiol. 1995, 76, 69C-77C
  6. Levine G.N.; Keaney J.F.Jr.; Vita. J.A. Cholestrol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N. Engl. J. Med. 1995, 332, 512-521
  7. The Treating New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 2007, 357, 1301-1310
  8. Kannel, W.B.; Castelli, W.P.; Gordon, T.; McNamara, P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann. Intern. Med. 1971, 74, 1-12
  9. Harper, H.Aï¼›Mayers, P. Metabolism of Lipids, In Review of physiological chemistry; Harper, H.A., Ed.; Lange Medical Publications (McGraw-Hill Inc.): New York, NY, USA, 1967; 11th Edition, 251-287
  10. Endo, A.; Kurodai, M.; Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by ML-236A and ML-236B, fungal metabolites, having hypocholesterolemic activity. F.E.B.S. Lett. 1976, 72, 323-326
  11. Endo, A.; Kurodai, M.; Tsujita, Y. ML-236, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antiobitics 1976, 29, 1346-1348
  12. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman C et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci.USA 1980, 77, 3957-3961
  13. Todd, P.A.; Goa K.L. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990, 40, 583-607
  14. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383-1389
  15. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996, 335, 1001-1009
  16. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339, 1349-1357
  17. Athyros, V.G.; Papageorgiou, A.A.; Mercouris, B.R. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr. Med. Res. Opin. 2002, 18, 220-228
  18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360, 7-22
  19. Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360, 1623-1630
  20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reseach Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. J. A. M. A. 2002, 288, 2998-3007
  21. Stampfer, M.J.; Hu, B.H.; Manson, J.E.; Rimm, E.B.; Willett, W.C. Primary prevention of coronary heart disease in women trough diet and lifestyle. N. Engl. J. Med. 2000, 343, 16-22
  22. The American Heart Association and the American College of Cardiology. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. Circulation 1999, 100, 1481-1492
  23. Oh, K.; Hu, F.B.; Manson, J.E.; Stamper, M.J..; Willett, W.C. Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses’ health study. Am. J. Epidemol. 2005, 161, 672-679
  24. Hu, F.B.; Willett, W.C. Optimal diets for prevention of coronary heart disease. J. A.M.A. 2002, 288, 2569-2578
  25. The Japan Collaborative Cohort Study for Evaluation of Cancer Risk Sponsored by Monbusho. Perceived mental stress and mortality from cardiovascular disease among Japanese men and women: the Japan collaborative cohort study for evaluation of cancer risk sponsored by Monbusho. Circulation 2002, 106, 1229-1236
  26. Wood, P.D.; Stefanick, M.L.; Williams, P.T.; Haskell, W.L.. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N. Engl. J. Med. 2012, 325, 461-466
  27. The Japan Collaborative Cohort Study Group. Healthy lifestyle behaviours and cardiovascular mortality among Japanese men and women: the Japan collaborative cohort study. Eur. Heart J. 2012, 33, 467-477
  28. Friedewald, W.T.; Levy, R.I.; Fredrickson, R.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499-502
  29. Mochizuki, T.; Ueda, A.; Ishinaga, M. Daily intakes of fatty acids, steriods and phospholipids by Japanese men. J. Jpn. Soc. Nutr. Food. Sci. 1998, 51, 339-343
  30. National Heart, Lung, and Blood Institute/American College of Cardiology Foundation/American Heart Association. Imolicationes of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110, 227-239

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue June 2023

Volume 12, June 2023


Table of Contents



World-wide Delivery is FREE

Share this Issue with Friends:


Submit your Paper